[{"id":"8cf6d2b8-03ca-4dcf-8c18-cb9a81b9e7b5","acronym":"Nivokin","url":"https://clinicaltrials.gov/study/NCT05468294","created_at":"2022-07-21T11:55:03.265Z","updated_at":"2024-07-02T16:36:06.995Z","phase":"Phase 1/2","brief_title":"F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05468294 - Nivokin","lead_sponsor":"Philogen S.p.A.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • teleukin (F16-IL2)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/09/2017","start_date":" 03/09/2017","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2022-07-21"},{"id":"2ef3301a-4666-4b8f-b4d5-732e29ac4db4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01134250","created_at":"2021-01-18T04:30:32.856Z","updated_at":"2024-07-02T16:36:12.390Z","phase":"Phase 1/2","brief_title":"Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients","source_id_and_acronym":"NCT01134250","lead_sponsor":"Philogen S.p.A.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • teleukin (F16-IL2)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 08/06/2008","start_date":" 08/06/2008","primary_txt":" Primary completion: 04/07/2014","primary_completion_date":" 04/07/2014","study_txt":" Completion: 04/07/2014","study_completion_date":" 04/07/2014","last_update_posted":"2022-04-15"}]